



MAX FEHLMANN

PhD, MBA

President and Chief Executive Officer
Institute Neo Med, Canada.

As President and CEO, Max Fehlmann is leading the entire NEOMED initiative in Montreal, Canada. Formerly President and Founder of CQDM (a pre-competitive consortium in drug discovery in Montreal), Max played a critical role in aligning emerging innovations from both academic institutions and SMEs with the needs of the industry. During

his career, Max has been deeply involved in the three fundamental pillars associated with the NEOMED Institute, namely academic research (Forgarty International Fellow at Harvard Medical School, Professor of Pharmacology at the University of Nice in France, Research Director at INSERM in France), SME management (Founder and CEO of Aster Biotechnologies in France and CEO of Chronogen in Montreal), and pharma R&D (Vice-President R&D for Zambon Group in Italy responsible for all pre-clinical, clinical, and licensing activities of the group worldwide).

Max holds a PhD in Biochemistry from *Université Laval*, a Doctorat of Sciences from the University of Nice (France), and an MBA from HEC-CPA at Sophia Antipolis (France). He has received numerous scientific and business awards throughout his career in Europe and Canada. Recently, Dr. Fehlmann was appointed Assistant Professor in the Department of Management of the Faculty of Administration at the *Université de Sherbrooke*.